典型文献
The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer
文献摘要：
Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non-small-cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD-1) and its ligand (PD-L1), have remarkable antitumor efficacy and have been approved as a standard first- or second-line treatment in non-oncogene-addicted advanced NSCLC. The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long-term overall survival and curative rates. In this review, we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer. We reviewed the early-phase results from neoadjuvant clinical trials, the landscape of the majority of ongoing phase III trials, and discuss the prospects of ICIs as a curative therapy for resectable lung cancer. We also summarized the potential biomarkers and beneficiaries involved in the current study, as well as the remaining unresolved challenges for neoadjuvant immunotherapy.
文献关键词：
immune checkpoint inhibitors;neoadjuvant treatment;non-small-cell lung cancer
中图分类号：
作者姓名：
Li Fajiu;Chen Ying;Wu Juanjuan;Li Chenghong;Chen Shi;Zhu Ziyang;Qin Wei;Liu Min;Hu Bingzhu;Liu Shuang;Zhong Wenzhao
作者机构：
Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Jianghan University, Wuhan, Hubei, China;Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
文献出处：
引用格式：
[1]Li Fajiu;Chen Ying;Wu Juanjuan;Li Chenghong;Chen Shi;Zhu Ziyang;Qin Wei;Liu Min;Hu Bingzhu;Liu Shuang;Zhong Wenzhao-.The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer)[J].慢性疾病与转化医学（英文）,2022(02):100-111
A类：
addicted
B类：
earlier,better,neoadjuvant,immunotherapy,resectable,small,cell,lung,cancer,Immune,inhibitors,ICIs,have,revolutionized,approach,advanced,locally,NSCLC,Antibodies,blocking,inhibitory,immune,checkpoints,such,programmed,death,its,ligand,L1,remarkable,antitumor,efficacy,been,approved,standard,first,second,line,treatment,oncogene,successful,application,motivated,researchers,further,evaluate,clinical,role,setting,improved,long,term,overall,survival,curative,rates,In,this,discuss,efforts,that,incorporate,into,paradigm,surgically,We,reviewed,early,phase,results,from,trials,landscape,majority,ongoing,III,prospects,also,summarized,potential,biomarkers,beneficiaries,involved,current,study,well,remaining,unresolved,challenges
AB值：
0.541268
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
